August 12, 2025

Ocular Therapeutix Announces FDA Approves NPDR Trial Plan for OTX-TKI

A Special Protocol Assessment (SPA) establishes a regulatory path for Ocular Therapeutix’s Axpaxli in diabetic eye disease.

Ophthalmology Management

August 12, 2025

Exonate Initiates Phase IIb Trial of EXN407 for Diabetic Eye Disease

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema

The Ophthalmologist

August 11, 2025

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME

The positive results from the SPECTRA trial demonstrate the tolerability and consistent, durable clinical activity of 4D-150 in DME.

Ophthalmology Management

August 08, 2025

How Many Vacation Days Are Doctors Taking?

A survey by the American Medical Association shows a rise in physicians taking time off, reflecting an improvement in burnout rates.

Conexiant

August 05, 2025

Large US Study Adds to Connection Between NAION Risks and GLP-1 Drugs

Semaglutide and liraglutide showed the highest risk, while dulaglutide and exenatide were not significantly associated with NAION.

Ophthalmology Management

July 01, 2025

Rapid Developments in Geographic Atrophy

The first treatments for GA were approved just 2 years ago, in 2023. While they slow progression, there’s a need for agents that would ideally prevent or reverse GA—or that would slow GA progression to a greater degree.

Ophthalmology Management

July 14, 2025

Dietary Nutrients and Diabetic Retinopathy

Explore the significant role of micronutrients in preventing and managing diabetic eye diseases, particularly diabetic retinopathy, as highlighted in the review by Dr. Samuel Asanad.

Retinal Physician

July 30, 2025

August is Children’s Eye Health and Safety Month

Prevent Blindness provides new resources

Optometric Management

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician